Buscar
11/05/2023
Contribution of Elevated Glucose and Oxidized LDL to Macrophage Inflammation: A Role for PRAS40/Akt-Dependent Shedding of Soluble CD14
Sanjurjo, L, Castelblanco, E, Julve, J, Villalmanzo, N, Tellez, E, Ramirez-Morros, A, Alonso, N, Mauricio, D, Sarrias, MR. Contribution of Elevated Glucose and Oxidized LDL to Macrophage Inflammation: A Role for PRAS40/Akt-Dependent Shedding of Soluble CD14. Antioxidants. 2023; 12(5)DOI:10.3390/antiox12051083. PMID:37237950. IF:6.000(Q1/2D).
08/05/2023
Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study
Goh, SY, Kosiborod, MN, Lam, CSP, Cavender, MA, Kohsaka, S, Norhammar, A, Birkeland, KI, Holl, RW, Mauricio, D, Tangri, N, Shaw, JE, Thuresson, M, Fenici, P, Kim, DJ. Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study. DIABETES OBESITY & METABOLISM. 2023; 25(8)DOI:10.1111/dom.15092. PMID:37055714. IF:5.400(Q1/2D).
01/05/2023
Gestational weight gain and pregnancy outcomes in women with type 1 and type 2 diabetes mellitus
Xie X., Liu J., García-Patterson A., Chico A., Mateu-Salat M., Amigó J., Adelantado J.M., Corcoy R.. Gestational weight gain and pregnancy outcomes in women with type 1 and type 2 diabetes mellitus. ACTA DIABETOLOGICA. 2023; 60(5)DOI:10.1007/s00592-023-02031-0. PMID:36707439. IF:3.100(Q2/5D).
01/05/2023
Research Priorities for Precision Medicine in NAFLD
Iruzubieta, P, Bataller, R, Arias-Loste, MT, Arrese, M, Calleja, JL, Castro-Narro, G, Cusi, K, Dillon, JF, Martinez-Chantar, ML, Mateo, M, Perez, A, Rinella, ME, Romero-Gomez, M, Schattenberg, JM, Zelber-Sagi, S, Crespo, J, Lazarus, JV. Research Priorities for Precision Medicine in NAFLD. Clinics in Liver Disease. 2023; 27(2)DOI:10.1016/j.cld.2023.01.016. PMID:37024222. IF:2.900(Q2/5D).